Monitor for any future conversion to a Schedule 13D (activist filing) — Millennium is a multi-strategy firm that occasionally engages actively. The 7.4% stake is just below the 10% level where additional reporting triggers apply. The next quarterly 13F will reveal cost basis and any hedging activity.
Price Chart
Executive Summary
Millennium Management (via Integrated Core Strategies) filed an amended Schedule 13G disclosing a 7.4% passive stake in Collegium Pharmaceutical as of September 30, 2026. The filing confirms a significant increase from the prior filing period, with Millennium entities now holding 2,400,985 shares. The passive certification (Rule 13d-1(c)) indicates no activist intent, but the increased stake signals growing conviction from a major multi-strategy fund.
Key Financial Metrics
Key Facts
- Millennium Management LLC and affiliates now beneficially own 2,400,985 shares (7.4% of common stock) as of September 30, 2026.
- Integrated Core Strategies (US) LLC directly holds 1,897,471 shares (5.8%).
- Filing is an amendment to Schedule 13G under Rule 13d-1(c) — passive investment, no activist intent.
- Joint filing agreement dated October 7, 2026, covers Integrated Core Strategies, Millennium Management, Millennium Group Management, and Israel A. Englander.
- Prior 13G filings from Fuller & Thaler (August 14) and Principal Global Investors (August 5) were also passive — no prior Millennium filing on record in the cross-filing context.
Financial Impact
Millennium's 7.4% stake is a notable institutional position but below the 10% threshold that would trigger additional disclosure requirements. No transaction prices or total value disclosed.
Risk Factors
- Millennium could reduce or exit the position at any time — 13G amendments are filed annually or upon material change, not in real time.
- Passive certification means no near-term catalyst from this filer; the stock remains subject to broader sector and company-specific risks.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001104659-26-114760 |
| Document: 0001104659-26-114760-index-headers.html | 0001104659-26-114760 |
| Document: 0001104659-26-114760-index.html | 0001104659-26-114760 |
| Document: 0001104659-26-114760.txt | 0001104659-26-114760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $23.50 $22.96 | ▼ −2.30% | ▼ −1.78% | $23.10 (−1.70%) |
Oct 19, 2026 7d ago | 8-K | $23.23 $22.92 | ▼ −1.36% | ▼ −1.88% | $23.10 (−0.56%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.09 $22.05 | ▼ −0.18% | ▼ −0.12% | $23.10 (+4.57%) |
Aug 19, 2026 9w ago | Court Ruling | $27.54 $27.11 | ▼ −1.56% | ▼ −1.97% | $23.10 (−16.12%) |
Aug 13, 2026 10w ago | 8-K | $28.15 $28.23 | ▲ +0.28% | ▲ +0.48% | $23.10 (−17.94%) |
Aug 6, 2026 11w ago | 8-K | $29.11 $29.47 | ▲ +1.24% | ▲ +0.63% | $23.10 (−20.65%) |
May 15, 2026 23w ago | Insider Cluster | $33.65 $33.62 | ▼ −0.09% | ▲ +0.56% | $23.10 (−31.35%) |
May 12, 2026 24w ago | Press Release | $35.69 $34.87 | ▼ −2.30% | ▼ −2.87% | $23.10 (−35.28%) |
May 11, 2026 24w ago | 144 | $35.81 $35.69 | ▼ −0.34% | ▼ −0.20% | $23.10 (−35.49%) |
Apr 23, 2026 26w ago | Press Release | $32.28 $32.50 | ▲ +0.68% | ▼ −0.10% | $23.10 (−28.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers